-DOCSTART- -X- O
Serious -X- _ O
viral -X- _ O
infections -X- _ O
are -X- _ O
a -X- _ O
common -X- _ O
cause -X- _ O
of -X- _ O
morbidity -X- _ O
and -X- _ O
mortality -X- _ O
after -X- _ O
allogeneic -X- _ B-Patient
stem -X- _ I-Patient
cell -X- _ I-Patient
transplantation. -X- _ I-Patient
They -X- _ O
occur -X- _ O
in -X- _ O
the -X- _ O
majority -X- _ O
of -X- _ O
allograft -X- _ O
recipients -X- _ O
and -X- _ O
are -X- _ O
fatal -X- _ O
in -X- _ O
17â€“20 -X- _ O
% -X- _ O
. -X- _ O
These -X- _ O
severe -X- _ O
infections -X- _ O
may -X- _ O
be -X- _ O
prolonged -X- _ O
or -X- _ O
recurrent -X- _ O
and -X- _ O
add -X- _ O
substantially -X- _ O
to -X- _ O
the -X- _ O
cost -X- _ O
, -X- _ O
both -X- _ O
human -X- _ O
and -X- _ O
financial -X- _ O
, -X- _ O
of -X- _ O
the -X- _ O
procedure. -X- _ O
Many -X- _ O
features -X- _ O
of -X- _ O
allogeneic -X- _ O
stem -X- _ O
cell -X- _ O
transplantation -X- _ O
contribute -X- _ O
to -X- _ O
this -X- _ O
high -X- _ O
rate -X- _ O
of -X- _ O
viral -X- _ O
disease. -X- _ O
The -X- _ O
cytotoxic -X- _ B-Intervention
and -X- _ I-Intervention
immunosuppressive -X- _ I-Intervention
drugs -X- _ I-Intervention
administered -X- _ B-Outcome
pre- -X- _ I-Outcome
transplant -X- _ I-Outcome
to -X- _ I-Outcome
eliminate -X- _ I-Outcome
the -X- _ I-Outcome
host -X- _ I-Outcome
hematopoietic -X- _ I-Outcome
/ -X- _ I-Outcome
immune -X- _ I-Outcome
system -X- _ I-Outcome
and -X- _ I-Outcome
any -X- _ I-Outcome
associated -X- _ I-Outcome
malignancy -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
delay -X- _ I-Outcome
in -X- _ I-Outcome
recapitulating -X- _ I-Outcome
immune -X- _ I-Outcome
ontogeny -X- _ I-Outcome
post-transplant -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
immunosuppressive -X- _ I-Outcome
drugs -X- _ I-Outcome
given -X- _ I-Outcome
to -X- _ I-Outcome
prevent -X- _ I-Outcome
graft -X- _ I-Outcome
versus -X- _ I-Outcome
host -X- _ I-Outcome
disease -X- _ I-Outcome
( -X- _ I-Outcome
GvHD -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
the -X- _ I-Outcome
effects -X- _ I-Outcome
of -X- _ I-Outcome
GvHD -X- _ I-Outcome
itself -X- _ I-Outcome
, -X- _ I-Outcome
all -X- _ I-Outcome
serve -X- _ I-Outcome
to -X- _ I-Outcome
make -X- _ I-Outcome
stem -X- _ I-Outcome
cell -X- _ I-Outcome
transplant -X- _ I-Outcome
recipients -X- _ I-Outcome
vulnerable -X- _ I-Outcome
to -X- _ I-Outcome
disease -X- _ I-Outcome
from -X- _ I-Outcome
endogenous -X- _ I-Outcome
( -X- _ I-Outcome
latent -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
exogenous -X- _ I-Outcome
( -X- _ I-Outcome
community -X- _ I-Outcome
) -X- _ I-Outcome
viruses -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
to -X- _ I-Outcome
be -X- _ I-Outcome
incapable -X- _ I-Outcome
of -X- _ I-Outcome
controlling -X- _ I-Outcome
them -X- _ I-Outcome
as -X- _ I-Outcome
quickly -X- _ I-Outcome
and -X- _ I-Outcome
effectively -X- _ I-Outcome
as -X- _ I-Outcome
most -X- _ I-Outcome
normal -X- _ I-Outcome
individuals -X- _ I-Outcome
. -X- _ O

